TC 6499

Drug Profile

TC 6499

Alternative Names: TC-6499; TC-6499-12

Latest Information Update: 20 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Targacept
  • Developer GlaxoSmithKline; Targacept
  • Class Irritable bowel syndrome therapies; Non-opioid analgesics; Small molecules
  • Mechanism of Action Alpha3beta4 nicotinic receptor agonists; Alpha4beta2 nicotinic receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Diabetic gastroparesis; Irritable bowel syndrome; Neuropathic pain

Most Recent Events

  • 18 Oct 2016 Catalyst Biosciences enters into a definitive agreement with an undisclosed partner for the divestiture of its neuronal nicotinic receptor, TC 6499
  • 16 Apr 2015 Discontinued - Phase-I/II for Diabetic gastroparesis in USA (PO)
  • 16 Apr 2015 Targacept completes a phase I/II trial for Diabetic gastroparesis in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top